PT  - JOURNAL ARTICLE
AU  - Brigitte Michelsen
AU  - Ulf Lindström
AU  - Catalin Codreanu
AU  - Adrian Ciurea
AU  - Jakub Zavada
AU  - Anne Gitte Loft
AU  - Manuel Pombo-Suarez
AU  - Fatos Onen
AU  - Tore K Kvien
AU  - Ziga Rotar
AU  - Maria Jose Santos
AU  - Florenzo Iannone
AU  - Anna-Mari Hokkanen
AU  - Bjorn Gudbjornsson
AU  - Johan Askling
AU  - Ruxandra Ionescu
AU  - Michael J Nissen
AU  - Karel Pavelka
AU  - Carlos Sanchez-Piedra
AU  - Servet Akar
AU  - Joseph Sexton
AU  - Matija Tomsic
AU  - Helena Santos
AU  - Marco Sebastiani
AU  - Jenny Österlund
AU  - Arni Jon Geirsson
AU  - Gary Macfarlane
AU  - Irene van der Horst-Bruinsma
AU  - Stylianos Georgiadis
AU  - Cecilie Heegaard Brahe
AU  - Lykke Midtbøll Ørnbjerg
AU  - Merete Lund Hetland
AU  - Mikkel Østergaard
TI  - Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
AID  - 10.1136/rmdopen-2020-001280
DP  - 2020 Sep 01
TA  - RMD Open
PG  - e001280
VI  - 6
IP  - 3
4099  - http://rmdopen.bmj.com/content/6/3/e001280.short
4100  - http://rmdopen.bmj.com/content/6/3/e001280.full
SO  - RMD Open2020 Sep 01; 6
AB  - Objectives To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries.Methods Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)).Results We included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70–93%, 12-month: 53–86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/84%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness.Conclusions In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12 months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries.